Patent EP3893930A1: Monoclonal Antibodies Against Human Dickkopf3
Summary
The European Patent Office has published patent application EP3893930A1 concerning monoclonal antibodies against human Dickkopf3 and their uses. The patent was published on March 11, 2026, with the Board of Regents, The University of Texas System listed as the applicant.
What changed
This document is a publication of a European patent application (EP3893930A1) related to monoclonal antibodies targeting human Dickkopf3. The patent application was published by the European Patent Office (EPO) on March 11, 2026. The applicant is the Board of Regents, The University of Texas System.
This is a patent publication, not a regulatory rule or guidance. It does not impose new compliance obligations on regulated entities. Companies operating in the pharmaceutical or biotechnology sectors may wish to review this patent for potential intellectual property considerations or to understand the landscape of antibody development in this area.
Source document (simplified)
MONOCLONAL ANTIBODIES AGAINST HUMAN DICKKOPF3 AND USES THEREOF
Publication EP3893930A1 Kind: A1 Mar 11, 2026
Applicants
Board of Regents, The University of Texas System
Inventors
HWANG, Rosa, ZHOU, Liran, LU, Mason, HUSTED, Hongmei, LOGSDON, Craig, LEE, Jeffrey, E.
IPC Classifications
C07K 16/28 20060101AFI20220715BHEP A61K 39/395 20060101ALI20220715BHEP C07D 307/04 20060101ALI20220715BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Peptides (C07K) publishes new changes.